183 related articles for article (PubMed ID: 18654117)
21. Molecularly targeted therapies for renal cell cancer: TRAIL research advances.
Buttyan R; Mian BM
J Urol; 2007 May; 177(5):1606. PubMed ID: 17437767
[No Abstract] [Full Text] [Related]
22. Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique.
Salmon HW; Mladinich C; Siemann DW
Eur J Cancer; 2006 Nov; 42(17):3073-8. PubMed ID: 16956760
[TBL] [Abstract][Full Text] [Related]
23. Temsirolimus for advanced renal cell carcinoma.
Figlin RA
Clin Adv Hematol Oncol; 2007 Nov; 5(11):893. PubMed ID: 18185488
[No Abstract] [Full Text] [Related]
24. Multifocal capillary hemangioma-like vascular proliferation of the kidney associated with clear cell renal cell carcinoma: a case report and review of the literature.
Fellegara G; Rosai J
Int J Surg Pathol; 2013 Aug; 21(4):424-6. PubMed ID: 23364358
[TBL] [Abstract][Full Text] [Related]
25. Targeted molecular therapy for renal cell carcinoma.
Lane BR; Rini BI; Novick AC; Campbell SC
Urology; 2007 Jan; 69(1):3-10. PubMed ID: 17270598
[No Abstract] [Full Text] [Related]
26. FGFR1 is associated with c-MYC and proangiogenic molecules in metastatic renal cell carcinoma under anti-angiogenic therapy.
Park JY; Kim PJ; Shin SJ; Lee JL; Cho YM; Go H
Histopathology; 2020 May; 76(6):838-851. PubMed ID: 31990416
[TBL] [Abstract][Full Text] [Related]
27. Complexity of tumor vasculature in clear cell renal cell carcinoma.
Qian CN; Huang D; Wondergem B; Teh BT
Cancer; 2009 May; 115(10 Suppl):2282-9. PubMed ID: 19402071
[TBL] [Abstract][Full Text] [Related]
28. Novel therapeutics for metastatic renal cell carcinoma.
Hutson TE; Figlin RA
Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-2 continuous infusion and angiogenesis surrogate markers in metastatic renal cell carcinoma.
Simonelli C; Talamini R; Bearz A; Berretta M; Spazzapan S; Monini P; Sgadari C; Sartor I; Ensoli B; Tirelli U
Ann Oncol; 2006 Aug; 17(8):1335-6. PubMed ID: 16569648
[No Abstract] [Full Text] [Related]
30. Sinomenine hydrochloride attenuates the proliferation, migration, invasiveness, angiogenesis and epithelial-mesenchymal transition of clear-cell renal cell carcinoma cells via targeting Smad in vitro.
Zhao B; Liu L; Mao J; Liu K; Fan W; Liu J; Zhang Z; Li Q
Biomed Pharmacother; 2017 Dec; 96():1036-1044. PubMed ID: 29198924
[TBL] [Abstract][Full Text] [Related]
31. One decade of improving palliative care of metastatic renal cell carcinoma by antiangiogenic therapies: time to move toward RCC cure.
Kroeger N; Zimmermann U; Burchardt M
Int J Cancer; 2015 Apr; 136(7):1483-4. PubMed ID: 25230294
[No Abstract] [Full Text] [Related]
32. Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma.
Mollica V; Massari F
Lancet Oncol; 2023 May; 24(5):423-425. PubMed ID: 37011649
[No Abstract] [Full Text] [Related]
33. Perspective: What next for treatment?
Motzer RJ
Nature; 2016 Sep; 537(7620):S111. PubMed ID: 27626781
[No Abstract] [Full Text] [Related]
34. Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors.
Caro J; Morales E; Gutierrez E; Ruilope LM; Praga M
J Clin Hypertens (Greenwich); 2013 Mar; 15(3):215-6. PubMed ID: 23458595
[No Abstract] [Full Text] [Related]
35. [Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management].
Audenet F; Rouprêt M; Méjean A
Prog Urol; 2009 Oct; 19(9):596-605. PubMed ID: 19800548
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapy: An elusive cancer target.
Brown C
Nature; 2016 Sep; 537(7620):S106-8. PubMed ID: 27626779
[No Abstract] [Full Text] [Related]
37. Renal cell carcinoma.
Mulders PF
World J Urol; 2008 Apr; 26(2):113. PubMed ID: 18389254
[No Abstract] [Full Text] [Related]
38. Review on targeted treatment of patients with advanced-stage renal cell carcinoma: a medical oncologist's perspective.
Tanriverdi O
Asian Pac J Cancer Prev; 2013; 14(2):609-17. PubMed ID: 23621207
[TBL] [Abstract][Full Text] [Related]
39. [Renal cell carcinoma: antiangiogenic therapies and management of the complications. A case report].
Fendler JP; Malavaud B; Gimel P; Duclos B; Chevreau C; Pignot G
Prog Urol; 2010 Mar; 20 Suppl 1():S27-32. PubMed ID: 20493440
[TBL] [Abstract][Full Text] [Related]
40. Update on the use of mTOR inhibitors in renal cell carcinoma.
Rini BI
Clin Adv Hematol Oncol; 2008 Oct; 6(10):722-4. PubMed ID: 18997660
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
